Avastin Biosimilar Battle: Amgen, Genentech File Dueling Suits

Amgen seeks declaratory judgement that its biosimilar Mvasi does not infringe 27 Genentech patents, has Genentech suit put under seal; Amgen gave 180-day commercial marketing notice on Oct. 6.

Patent Law Concept 3D Illustration

More from Biosimilars

More from Biosimilars & Generics